Literature DB >> 29635437

A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients.

Deepali Kumar1, Victor H Ferreira1, Emily Blumberg2, Fernanda Silveira3, Elisa Cordero4, Pilar Perez-Romero4, Teresa Aydillo4, Lara Danziger-Isakov5, Ajit P Limaye6, Jordi Carratala7, Patricia Munoz8, Miguel Montejo9, Francisco Lopez-Medrano10, Maria Carmen Farinas11, Joan Gavalda12, Asuncion Moreno13, Marilyn Levi14, Jesus Fortun15, Julian Torre-Cisneros16, Janet A Englund17, Yoichiro Natori1, Shahid Husain1, Gail Reid18, Tanvi S Sharma19, Atul Humar1.   

Abstract

Background: Seasonal influenza infection may cause significant morbidity and mortality in transplant recipients. The purpose of this study was to assess the epidemiology of symptomatic influenza infection posttransplant and determine risk factors for severe disease.
Methods: Twenty centers in the United States, Canada, and Spain prospectively enrolled solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT) recipients with microbiologically confirmed influenza over 5 consecutive years (2010-2015). Demographics, microbiology data, and outcomes were collected. Serial nasopharyngeal swabs were collected at diagnosis and upto 28 days, and quantitative polymerase chain reaction for influenza A was performed.
Results: We enrolled 616 patients with confirmed influenza (477 SOT; 139 HSCT). Pneumonia at presentation was in 134 of 606 (22.1%) patients. Antiviral therapy was given to 94.1% for a median of 5 days (range, 1-42 days); 66.5% patients were hospitalized and 11.0% required intensive care unit (ICU) care. The receipt of vaccine in the same influenza season was associated with a decrease in disease severity as determined by the presence of pneumonia (odds ratio [OR], 0.34 [95% confidence interval {CI}, .21-.55], P < .001) and ICU admission (OR, 0.49 [95% CI, .26-.90], P = .023). Similarly, early antiviral treatment (within 48 hours) was associated with improved outcomes. In patients with influenza A, pneumonia, ICU admission, and not being immunized were also associated with higher viral loads at presentation (P = .018, P = .008, and P = .024, respectively). Conclusions: Annual influenza vaccination and early antiviral therapy are associated with a significant reduction in influenza-associated morbidity, and should be emphasized as strategies to improve outcomes of transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29635437     DOI: 10.1093/cid/ciy294

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  38 in total

1.  Underimmunization of the solid organ transplant population: An urgent problem with potential digital health solutions.

Authors:  Amy G Feldman; Katherine Atkinson; Kumanan Wilson; Deepali Kumar
Journal:  Am J Transplant       Date:  2019-10-28       Impact factor: 8.086

2.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

3.  Outcomes of Immunocompromised Adults Hospitalized With Laboratory-confirmed Influenza in the United States, 2011-2015.

Authors:  Jennifer P Collins; Angela P Campbell; Kyle Openo; Monica M Farley; Charisse Nitura Cummings; Mary Hill; William Schaffner; Mary Lou Lindegren; Ann Thomas; Laurie Billing; Nancy Bennett; Nancy Spina; Marisa Bargsten; Ruth Lynfield; Seth Eckel; Patricia Ryan; Kimberly Yousey-Hindes; Rachel Herlihy; Pam Daily Kirley; Shikha Garg; Evan J Anderson
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

4.  Cervical Cytokines Associated With Chlamydia trachomatis Susceptibility and Protection.

Authors:  Taylor B Poston; De'Ashia E Lee; Toni Darville; Wujuan Zhong; Li Dong; Catherine M O'Connell; Harold C Wiesenfeld; Sharon L Hillier; Gregory D Sempowski; Xiaojing Zheng
Journal:  J Infect Dis       Date:  2019-06-19       Impact factor: 5.226

Review 5.  Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Authors:  Mini Kamboj; Monika K Shah
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

Review 6.  Antiviral Therapeutics in Pediatric Transplant Recipients.

Authors:  William R Otto; Abby Green
Journal:  Infect Dis Clin North Am       Date:  2022-03       Impact factor: 5.982

Review 7.  Infectious complications and vaccines.

Authors:  Per Ljungman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

8.  SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns.

Authors:  Arnaud G L'Huillier; Lara Danziger-Isakov; Abanti Chaudhuri; Michael Green; Marian G Michaels; Klara M Posfay-Barbe; Dimitri van der Linden; Anita Verma; Mignon McCulloch; Monica I Ardura
Journal:  Pediatr Transplant       Date:  2021-03-10

9.  Hospitalizations for vaccine-preventable infections among pediatric hematopoietic cell transplantation recipients in the first 5 years after transplantation.

Authors:  Dana Danino; Joseph R Stanek; Hemalatha Rangarajan; Monica I Ardura
Journal:  Bone Marrow Transplant       Date:  2021-06-21       Impact factor: 5.483

Review 10.  Early detection of SARS-CoV-2 and other infections in solid organ transplant recipients and household members using wearable devices.

Authors:  Brendan J Keating; Eyas H Mukhtar; Eric D Elftmann; Feyisope R Eweje; Hui Gao; Lina I Ibrahim; Ranganath G Kathawate; Alexander C Lee; Eric H Li; Krista A Moore; Nikhil Nair; Venkata Chaluvadi; Janaiya Reason; Francesca Zanoni; Alexander T Honkala; Amein K Al-Ali; Fatima Abdullah Alrubaish; Maha Ahmad Al-Mozaini; Fahad A Al-Muhanna; Khaldoun Al-Romaih; Samuel B Goldfarb; Ryan Kellogg; Krzysztof Kiryluk; Sarah J Kizilbash; Taisa J Kohut; Juhi Kumar; Matthew J O'Connor; Elizabeth B Rand; Robert R Redfield; Benjamin Rolnik; Joseph Rossano; Pablo G Sanchez; Arash Alavi; Amir Bahmani; Gireesh K Bogu; Andrew W Brooks; Ahmed A Metwally; Tejas Mishra; Stephen D Marks; Robert A Montgomery; Jay A Fishman; Sandra Amaral; Pamala A Jacobson; Meng Wang; Michael P Snyder
Journal:  Transpl Int       Date:  2021-05-05       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.